EUCTR2020-000547-31-ES进行中（未招募）1 期
Estudio abierto, multicéntrico y de extensión a largo plazo con pautas de zanubrutinib (BGB-3111) en pacientes con neoplasias malignas de linfocitos B
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. As part of a BeiGene parent study:
- •a. Currently participating, or
- •b. Participated recently
- •2. Intent to continue or start zanubrutinib treatment after occurrence of any of the following:
- •a. At time of final analysis or study closure of the eligible BeiGene parent study:
- •For zanubrutinib-naive patients, rationale for initiation of zanubrutinib treatment must be discussed with and approved by the medical monitor
- •b. At time of progressive disease (PD) after occurrence of either of the following:
- •i Patient was receiving zanubrutinib at the time of progressive disease (PD), and the investigator and patient agree it is in the patient’s best interest to continue zanubrutinib (discussion with and approval by the medical monitors of the parent study and this study required)
- •ii Patient was receiving a non-BTK inhibitor drug at the time of progressive disease (PD), and the investigator and patient agree that the patient may clinically benefit from zanubrutinib treatment (discussion with and approval by the medical monitors of the parent study and this study required)
- •c. At an alternative timepoint for an alternative reason (discussion with and approval by the medical monitor required)
- •3. Patient who is currently on zanubrutinib treatment:
- •Does not meet any criteria for zanubrutinib hold or permanent discontinuation, and, in the opinion of the investigator, will continue to benefit from zanubrutinib treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 154
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 546
排除标准
- •1. Permanently discontinued from zanubrutinib treatment in the BeiGene parent study due to unacceptable toxicity, noncompliance with study procedures, or withdrawal of consent
- •2. Uncontrolled active systemic infection or recent infection requiring parenteral anti-microbial therapy
- •3. Life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of zanubrutinib, or put the study outcomes at undue risk
- •4. Concomitant chemotherapy, targeted therapy, radiation therapy, antibody-based therapy, or any prohibited concomitant therapy outlined in the protocol
- •5. Pregnant or lactating woman
- •6. Inability to comply with study procedures
- •7. Concurrent participation in another therapeutic clinical study
- •8. History of progressive disease (PD) while receiving a BTK inhibitor (excluding zanubrutinib)
研究者
相似试验
进行中（未招募）
1 期
Estudio de extensión, multicéntrico, abierto, de 24 meses de duración para evaluar la seguridad de ranibizumab como tratamiento sintomático de la alteración visual secundaria a edema macular diabético en pacientes que han finalizado el ensayo RESTORE - RESTORE EXTENSIOEdema Macular DiabéticoMedDRA version: 9.1Level: LLTClassification code 10057934Term: Diabetic macular edemaEUCTR2008-007467-17-ESovartis Farmacéutica, S.A.
进行中（未招募）
不适用
Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con astrocitoma subependimario de células gigantes (SEGA) asociado con el complejo esclerosis tuberosa (TSC). ESTUDIO EFFECTS: Everolimus para acceso expandido acelerado en SEGA con TSC. - EFFECTS STUDYPacientes con astrocitoma subependimario de células gigantes (SEGA) asociado con el complejo esclerosis tuberosa (TSC)EUCTR2010-022583-13-ESovartis Farmaceútica S.A.250
进行中（未招募）
1 期
Estudio multicéntrico, abierto, de acceso expandido, de RO5185426 en pacientes con melanoma metastásico An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanomaEUCTR2010-023526-21-ESF. Hoffmann-La Roche Ltd.900
进行中（未招募）
不适用
Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con inhibidor de tirosina quinasas del receptor del factor de crecimiento endotelial vascular.EUCTR2007-005460-28-ESovartis Farmacéutica, S.A1,000
进行中（未招募）
1 期
Estudio multicéntrico, prospectivo, abierto para evaluar la farmacocinética, tolerabilidad, seguridad y eficacia de la formulación pediátrica de bosentan, dos veces frente a tres veces al día en niños con hipertensión arterial pulmonar - FUTURE 3EUCTR2010-021825-11-ESActelion Pharmaceuticals Ltd.64